GSK plc's RSV vaccine, Arexvy, was approved by the European Commission on January 26, 2026, for use in all adults aged 18 and older, expanding its previous approval for older age groups. In the EU, around 158,000 adults are hospitalized each year due to RSV-related illnesses.